Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 over exp||breast cancer||sensitive||FGFR2 Inhibitor||AZ8010||Preclinical||Actionable||In a preclinical study, AZ8010 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).||22869148|
|FGFR2 over exp||breast cancer||sensitive||FGFR2 Inhibitor||AZD4547||Preclinical||Actionable||In a preclinical study, AZD4547 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).||22869148|
|FGFR2 over exp||breast cancer||sensitive||PD173074||Preclinical||Actionable||In a preclinical study, PD173074 inhibited proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).||22869148|
|FGFR2 over exp||endometrial cancer||resistant||FGFR2 Inhibitor||AZD4547||Preclinical - Cell culture||Actionable||In a preclinical study, endometrial cells with Fgfr2 overexpression were resistant to the anti-proliferative effects of AZD4547 (PMID: 26294741).||26294741|
|FGFR2 over exp||colorectal cancer||sensitive||Aprutumab ixadotin||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Aprutumab ixadotin (BAY1187982) inhibited survival of colorectal cancer cells with over expressing Fgfr2 in culture, and suppressed tumor growth in cell line xenograft models (PMID: 27543601).||27543601|
|FGFR2 over exp||Advanced Solid Tumor||sensitive||FGFR Inhibitor (Pan)||PRN1371||Preclinical - Cell culture||Actionable||In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing wild-type FGFR2 in culture (PMID: 28978721).||28978721|
|FGFR2 over exp||Advanced Solid Tumor||sensitive||FGFR2 Inhibitor||Derazantinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells overexpressing Fgfr2 in culture and in cell line xenograft models (PMID: 27627808).||27627808|
|FGFR2 over exp||Advanced Solid Tumor||predicted - sensitive||FGFR Inhibitor (Pan)||Rogaratinib||Phase I||Actionable||In a Phase I trial, treatment with Rogaratinib (BAY 1163877) was well-tolerated and resulted in objective response rate (ORR) of 15% (15/100) in patients with FGFR1, FGFR2, or FGFR3-overexpressing advanced solid tumors, including urothelial cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer, and led to an ORR of 67% (10/15) in patients with FGFR overexpression, but without an FGFR genetic aberration (PMID: 31405822).||31405822|
|FGFR2 over exp||lung squamous cell carcinoma||no benefit||FGFR Inhibitor (Pan)||Rogaratinib||Phase II||Actionable||In a Phase II trial (SAKK 19/18), Rogaratinib (BAY 1163877) treatment did not meet its primary endpoint for 6-month progression-free survival (PFS) in patients with advanced lung squamous cell carcinoma with overexpression of FGFR1, FGFR2, or FGFR3, and resulted in only 6.7% (1/15) of patients achieving 6-month PFS, with no objective responses, a median PFS of 1.6 months, and a median overall survival of 3.5 months (PMID: 36099710; NCT03762122).||36099710|